302 related articles for article (PubMed ID: 28197787)
1. Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
Schimanski CC; Staib F; Göhler T; Hebart H; Heike M; Neise M; Rudi J; Geer T; Dingeldein G; Lang C; Ehscheidt P; Flohr T; Josten KM; Karthaus M; Schmittel A; Wierecky J; Boller E; Indorf M; Wörns MA; Galle PR; Moehler M
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1023-1034. PubMed ID: 28197787
[TBL] [Abstract][Full Text] [Related]
2. EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.
Hofheinz RD; Lorenzen S; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Tetyusheva M; Heeger S; Vlassak S; Merx K
Ann Oncol; 2018 Apr; 29(4):1010-1015. PubMed ID: 29360920
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
Cheng AL; Cornelio G; Shen L; Price T; Yang TS; Chung IJ; Dai GH; Lin JK; Sharma A; Yeh KH; Ma B; Zaatar A; Guan Z; Masood N; Srimuninnimit V; Yau T; Gibbs P; Wang X; Doval DC; Oh ST; Shim BY; Gorospe C; Wang HM; Sirachainan E; Hill A; Suh KW; Beier F; Chatterjee S; Lim R
Clin Colorectal Cancer; 2017 Jun; 16(2):e73-e88. PubMed ID: 27780749
[TBL] [Abstract][Full Text] [Related]
4. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A
JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468
[TBL] [Abstract][Full Text] [Related]
5. FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.
Köhne CH; Poston G; Folprecht G; Ciardiello F; Ronga P; Beier F; Van Cutsem E
Eur J Surg Oncol; 2016 Oct; 42(10):1540-7. PubMed ID: 27575968
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
Raoul JL; Van Laethem JL; Peeters M; Brezault C; Husseini F; Cals L; Nippgen J; Loos AH; Rougier P
BMC Cancer; 2009 Apr; 9():112. PubMed ID: 19366444
[TBL] [Abstract][Full Text] [Related]
7. Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy.
Yamaguchi K; Ando M; Ooki A; Beier F; Guenther S; von Hohnhorst P; Van Cutsem E
Clin Colorectal Cancer; 2017 Jun; 16(2):e29-e37. PubMed ID: 28081962
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
9. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
[TBL] [Abstract][Full Text] [Related]
10. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Michl M; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmueller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Mueller S; Lerch MM; Modest DP; Kirchner T; Jung A; Heinemann V;
Ann Oncol; 2016 Aug; 27(8):1565-72. PubMed ID: 27234640
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.
Iwamoto S; Hazama S; Kato T; Miyake Y; Fukunaga M; Matsuda C; Bando H; Sakamoto J; Oba K; Mishima H
Anticancer Res; 2014 Apr; 34(4):1967-73. PubMed ID: 24692733
[TBL] [Abstract][Full Text] [Related]
12. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
14. A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.
Boisdron-Celle M; Metges JP; Capitain O; Adenis A; Raoul JL; Lecomte T; Lam YH; Faroux R; Masliah C; Poirier AL; Berger V; Morel A; Gamelin E
Semin Oncol; 2017 Feb; 44(1):24-33. PubMed ID: 28395759
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
17. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
[TBL] [Abstract][Full Text] [Related]
18. Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial.
Kasper S; Meiler J; Knipp H; Höhler T; Reimer P; Steinmetz T; Berger W; Linden G; Reis H; Markus P; Paul A; Dechêne A; Schumacher B; Kostbade K; Virchow I; Ting S; Worm K; Schmid KW; Herold T; Wiesweg M; Schuler M; Trarbach T
Clin Colorectal Cancer; 2020 Dec; 19(4):236-247.e6. PubMed ID: 32737003
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]